Brief: Acorda Therapeutics Says Q4 Non-Gaap Loss Per Share $2.50

Acorda Therapeutics

04/03/2021 22:22

March 4 (Reuters) - Acorda Therapeutics Inc  ACOR.O :
    * SEES FY 2021 AMPYRA REVENUE $75 MILLION TO $85 MILLION
    * ACORDA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS
FOURTH
QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS
    * Q4 NON-GAAP LOSS PER SHARE $2.50
    * Q4 GAAP LOSS PER SHARE $9.82
    * TOTAL 2021 NON-GAAP OPERATING EXPENSE EXPECTED TO BE
$130-$140
MILLION
    * QTRLY TOTAL REVENUE $38.2 MILLION VERSUS $50.5 MILLION

Source text for Eikon:  urn:newsml:reuters.com:*:nBw272VlWa
Further company coverage:  ACOR.O 

 ((Reuters.Briefs@thomsonreuters.com;))